Phase 2 RCT in 254 adults with diabetic kidney disease: monlunabant 25 mg did not significantly reduce UACR at 16 weeks vs placebo (ratio 0.72, 95% CI 0.46–1.14). Gastrointestinal adverse events were common and withdrawals rose with dose.
RCTn = 254
Cherney et al. A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease